Unmet needs for new therapies and trial designs, particularly for patients with treatment-refractory disease, remain a top priority in rheumatology, international experts agree. Coming together at the 21st annual Advances in Targeted Therapies (ATT) meeting, more than 100 leading scientists and clinical researchers identified and prioritised unmet research needs in rheumatology, focusing on rheumatoid arthritis (RA), ...
Tackling treatment refractory disease a top priority in rheumatology: experts
By Jennie James
19 Nov 2019